GFI Clinical Services

GFI Clinical Services was a prominent Contract Research Organization (CRO) specializing in Phase I clinical trials and early-stage drug development services. Based in Evansville, Indiana, the company operated one of the largest independent Phase I facilities in the United States, providing clinical pharmacology services to the pharmaceutical and biotechnology industries. The company focused on conducting first-in-human studies, bioequivalence trials, and pharmacokinetic/pharmacodynamic assessments. In 2002, GFI was acquired by PPD (Pharmaceutical Product Development) for approximately $40 million to bolster its early-phase research capabilities. Following PPD's acquisition by Thermo Fisher Scientific in 2021, the legacy GFI operations continue as part of Thermo Fisher's clinical research business.